PMID- 8901839
OWN - NLM
STAT- MEDLINE
DCOM- 19961206
LR  - 20220419
IS  - 0194-911X (Print)
IS  - 0194-911X (Linking)
VI  - 28
IP  - 5
DP  - 1996 Nov
TI  - Polymorphisms of the transforming growth factor-beta 1 gene in relation to 
      myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du 
      Myocarde (ECTIM) Study.
PG  - 881-7
AB  - Transforming growth factor-beta 1 (TGF-beta 1) plays an important role in the 
      modulation of cellular growth and differentiation and the production and 
      degradation of the extracellular matrix. A number of experimental results suggest 
      that TGF-beta 1 may be involved in cardiovascular physiopathology. In the present 
      study, we assessed whether the TGF-beta 1 gene is a candidate gene for coronary 
      heart disease or hypertension. We screened the coding region and 2181 bp upstream 
      of the TGF-beta gene for polymorphisms and identified seven polymorphisms: 3 in 
      the upstream region of the gene at positions -988, -800, and -509 from the first 
      transcribed nucleotide; 1 in a nontranslated region at position +72; 2 in the 
      signal peptide sequence Leu10-->Pro, Arg25-->Pro; and 1 in the region of the gene 
      coding for the precursor part of the protein not present in the active form, 
      Thr263-->Ile. We analyzed these TGF-beta 1 polymorphisms in 563 patients with 
      myocardial infarction and 629 control subjects from four regions in Northern 
      Ireland and France. The Pro25 allele was more frequent in patients than in 
      control subjects in Belfast (P < .01) and Strasbourg (P < .05). The TGF-beta 1 
      polymorphisms were not associated with the degree of angiographically assessed 
      coronary artery disease in patients. The presence of a Pro25 allele was 
      associated with a lower systolic pressure in the four control groups (P < .002), 
      and a history of hypertension was significantly less frequent in homozygotes or 
      heterozygotes for Pro25 than in hormozygotes for Arg25 (odds ratio, 0.43, 95% 
      confidence interval, 0.19 to 0.92; P < .03). Since the Pro25 allele was 
      associated with an increased risk of myocardial infarction and a reduced risk of 
      hypertension, we favor a cautious interpretation of these apparently inconsistent 
      results. Other studies will need to verify whether these associations are real.
FAU - Cambien, F
AU  - Cambien F
AD  - INSERM SC7, Paris, France. cambien@infobiogen.fr
FAU - Ricard, S
AU  - Ricard S
FAU - Troesch, A
AU  - Troesch A
FAU - Mallet, C
AU  - Mallet C
FAU - Generenaz, L
AU  - Generenaz L
FAU - Evans, A
AU  - Evans A
FAU - Arveiler, D
AU  - Arveiler D
FAU - Luc, G
AU  - Luc G
FAU - Ruidavets, J B
AU  - Ruidavets JB
FAU - Poirier, O
AU  - Poirier O
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Hypertension
JT  - Hypertension (Dallas, Tex. : 1979)
JID - 7906255
RN  - 0 (Transforming Growth Factor beta)
SB  - IM
CIN - Hypertension. 1996 Nov;28(5):880. PMID: 8901838
MH  - Adult
MH  - Alleles
MH  - Blood Pressure/genetics
MH  - Genotype
MH  - Humans
MH  - Hypertension/*genetics
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*genetics
MH  - Polymorphism, Genetic
MH  - Transforming Growth Factor beta/*genetics
EDAT- 1996/11/01 00:00
MHDA- 1996/11/01 00:01
CRDT- 1996/11/01 00:00
PHST- 1996/11/01 00:00 [pubmed]
PHST- 1996/11/01 00:01 [medline]
PHST- 1996/11/01 00:00 [entrez]
AID - 10.1161/01.hyp.28.5.881 [doi]
PST - ppublish
SO  - Hypertension. 1996 Nov;28(5):881-7. doi: 10.1161/01.hyp.28.5.881.